<DOC>
	<DOCNO>NCT00878904</DOCNO>
	<brief_summary>RATIONALE : Panobinostat may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , epirubicin , work different way stop growth tumor cell , either kill cell stop divide . Giving panobinostat together epirubicin may kill tumor cell . PURPOSE : This phase I trial study side effect best dose panobinostat give together epirubicin treat patient metastatic malignant solid tumor .</brief_summary>
	<brief_title>Panobinostat Epirubicin Treating Patients With Metastatic Malignant Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine safety , tolerability , maximum tolerate dose ( MTD ) , recommend phase II dose panobinostat administer epirubicin hydrochloride patient metastatic malignant solid tumor . Secondary - To determine correlation pharmacokinetic profile panobinostat drug level pharmacodynamic effect panobinostat histone acetylation peripheral blood mononuclear cell ( PBMCs ) . - To determine effect panobinostat histone acetylation chromatin remodel protein ( HP-1 , DNMT-1 , SMC1-5 , Topo II ) . - To determine relevance HDAC1 , HDAC2 , HDAC3 , HDAC6 expression PBMCs pharmacological marker biopsied tumor predictive marker response patient treat MTD . - To document objective response patient . OUTLINE : This dose-escalation study panobinostat . Patients receive oral panobinostat day 1 , 3 , 5 epirubicin hydrochloride IV day 5 . Treatment repeat every 21 day 10 course absence disease progression unacceptable toxicity . Patients undergo blood sample collection baseline periodically course 1 panobinostat pharmacokinetic study . Patients enrol dose expansion cohort also undergo collection tumor tissue sample fine needle aspiration baseline day 5 course 1 ( panobinostat infusion ) . Blood tissue sample analyze histone acetylation , chromatin remodel gene protein ( HP-1 , DNMT-1 , SMC1-5 , Topo II ) , HDAC enzyme expression immunofluorescence western blotting .</detailed_description>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically histologically confirm solid tumor malignancy curative therapy exist Metastatic disease Measurable evaluable disease ( i.e. , elevate CA125 elevate PSA patient ovarian cancer prostate cancer , respectively ) Disease amenable biopsy AND patient willing undergo biopsy ( patient enrol dose expansion cohort ) No uncontrolled CNS metastasis Stable CNS metastasis allow provided patient undergone complete surgical resection , gamma knife radiotherapy ( isolated lesion ) wholebrain radiotherapy AND metastasis stable ≥ 6 week PATIENT CHARACTERISTICS : ECOG performance status 02 WBC &gt; 3,000/mm³ ANC &gt; 1,500/mm³ Hemoglobin &gt; 9.0 g/dL ( RBC transfusion allow ) Platelet count &gt; 100,000/mm³ AST/ALT ≤ 1.5 time upper limit normal ( ULN ) Serum bilirubin ≤ 1.3 time ULN Serum creatinine ≤ 1.5 time ULN OR creatinine clearance ≥ 50 mL/min 24hour urine collection Total serum calcium ( correct serum albumin ) ionize calcium ≥ low limit normal Serum potassium ≥ 4.0 mEq/L ( supplementation allow ) Serum magnesium normal ( supplementation allow ) Serum sodium ≥ 130 mEq/L Serum albumin ≥ 3 g/dL Elevated alkaline phosphatase gammaglutamyltransferase due bone metastasis liver metastasis allow Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod ( include barrier ) contraception 3 month completion study treatment QTc &lt; 460 m No evidence significant active infection ( e.g. , pneumonia , cellulitis , wound abscess ) No impaired cardiac function , include follow : Complete leave bundle branch block use permanent cardiac pacemaker Congenital long QT syndrome History presence ventricular tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTcF &gt; 470 msec screen ECG Right bundle branch block plus leave anterior hemiblock ( bifascicular block ) Atrial fibrillation ( ventricular heart rate &gt; 100 beat per minute ) Angina pectoris acute myocardial infarction within past 6 month New York Heart Association class IIIIV congestive heart failure LVEF &lt; 50 % baseline MUGA ECHO No history seizures PRIOR CONCURRENT THERAPY : No prior cumulative anthracycline dose &gt; 300 mg/m² doxorubicin hydrochloride &gt; 480 mg/m² epirubicin hydrochloride More 5 day since prior valproic acid More 3 week since prior concurrent chemotherapy , hormonal therapy , radiotherapy , experimental anticancer therapy primary disease No concurrent HDAC inhibitors No concurrent medication may induce torsades de pointes cause QTc prolongation No concurrent investigational anticancer therapy No concurrent CYP3A4 inhibitor ( include grapefruit grapefruit juice ) and/or CYP3A4 inducers No concurrent antiarrhythmic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>